FDA approves Vifor's hyperphosphatemia drug

12/2/2013 | PharmaTimes (U.K.)

Vifor Pharma has obtained federal approval for its Velphoro therapy for hyperphosphatemia in patients with chronic kidney disease who are undergoing dialysis. Data from a Phase III trial showed the drug fared better than Sanofi's Renvela in regulating phosphorus accumulation in the bloodstream.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD